期刊文献+

抑郁症伴或不伴糖尿病患者过夜小剂量地塞米松抑制试验的对照研究 被引量:13

Overnight low-dose dexamethasone suppression test in depressed patients with or without diabetes: a clinical control study
原文传递
导出
摘要 目的探讨下丘脑-垂体-肾上腺轴(HPA)功能异常在抑郁症患者伴发的糖尿病发病机制中的意义。方法首次诊断为糖尿病的抑郁症患者(病例组)、正常血糖稳态的抑郁症患者(对照组)各40例,于药物治疗前测定空腹血糖、糖负荷后2h血糖,并行过夜小剂量(1mg)地塞米松抑制试验。结果(1)病例组抑制前8:00、16:00及抑制后8:00血浆皮质醇浓度分别为(608±266)、(409±176)、(382±257)mmol/L,高于对照组的(499±199)、(299±148)、(232±182)nmol/L,差异均有统计学意义(P=0.042,P=0.003,P=0.004);(2)病例组地塞米松抑制试验脱抑制率为72%(29/40),高于对照组的42%(17/40),差异有统计学意义(P=0.007);(3)病例组抑制前8:00、抑制后8:00血浆皮质醇浓度分别与空腹血糖值正相关(r=0.392,r=0.470,P均〈0.05)。结论伴发糖尿病的抑郁症患者较正常血糖稳态的抑郁症患者存在更为显著的HPA功能异常,并可能是抑郁症患者伴发糖尿病的重要病理机制之一。 Objective To explore the possible role of bypotbalamie-pituitary-adrenal axis (HPA) dysfunction in mechanism of diabetes in depressive patients. Methods Two groups including depressed patients with newly diagnosed diabetes ( case group, n = 40) , depressed patients with normal glucose homeostasis (control group, n = 40) were included, and underlook overnight low-dose dexamethasone (1 mg) suppression test (LDDST) and fasting plasma glucose, 2 h plasma glucose after 75 g glucose loading measurement before medication. Results The plasma eortisol levels in case group at baseline time point of 8:00 and 16:00, and 8:00 after 1 mg dexamethasone were significantly higher than that in control group [ (608 ±266) nmol/L vs. (499 ± 199) nmoL/L; (409± 176) nmoL/L vs. (299±148) nmol/L; (382±257 ) nmol/L vs. (232±182 ) mnol/L; P = 0. 042,0. 003,0. 004 respectively ]. The escaped suppression rates in LDDST were significantly more in case group than control group (72% vs. 42% , P = 0. 007). Plasma eortisol levels at 8:00 before and after dexamethasone were positively correlated with fasting plasma glucose in case group (r = 0. 392, 0. 470 ; both P 〈 0. 05). Conclusion Depressed patients with diabetes have much severe dysfunction of the HPA axis which may play an important role in the pathomechanism of diabetes in depression.
机构地区 解放军第一
出处 《中华精神科杂志》 CAS CSCD 北大核心 2011年第2期112-115,共4页 Chinese Journal of Psychiatry
关键词 抑郁 糖尿病 氢化可的松 地塞米松抑制试验 Depression Diabetes mellitus Hydrocortisone Dexamethasone suppression test
  • 相关文献

参考文献16

  • 1Engum A, Mykletun A, Midthjell K, et al. Depression and diabetes: a large population-based study of soeiodemographic, lifestyle, and clinical factors associated with depression in type 1 and type 2 diabetes. Diabetes Care,2005,28:1904-1909. 被引量:1
  • 2Timonen M,Laakso M, Jokelainen J, et al. Insulin resistance and depression : cross sectional study. BMJ, 2005,330 : 17-18. 被引量:1
  • 3Golden SH. A review of the evidence for a neuroendoerine link between stress, depression and diabetes mellitus. Curt Diabetes Rev,2007,3:252-259. 被引量:1
  • 4Genuth S, Alberti KG, Bennett P,et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003, 26: 3160- 3167. 被引量:1
  • 5陈珏,肖泽萍,林治光,王克勋,邹政,徐勇,王振,张明岛.强迫症患者血小板5-羟色胺、血浆催乳素及地塞米松抑制试验的研究[J].中华精神科杂志,2004,37(1):14-17. 被引量:10
  • 6张炜,汤正义,黄昉,王卫庆,张毅,李小英,赵咏桔,胡仁明,宁光.诊断库欣综合征时多种检查方法的比较[J].中华内分泌代谢杂志,2005,21(5):402-404. 被引量:39
  • 7司天梅,舒良,丁新生,王崇顺,王维智,王晓平,文有生,朱沂,朱紫青,老洪尧,刘畅,许秀峰,陈佐明,范洪玉,周盛年,张聪沛,张宁,屈一凡,姜凤英,高政,索爱琴,唐济生,张晓庆,钱敏才,胡学强,郭田生,杨友松,蓝长安,彭国光,谭庆荣,程英科.西酞普兰治疗抑郁症的疗效及安全性的多中心临床研究[J].中华精神科杂志,2005,38(4):222-226. 被引量:38
  • 8Kunugi H, Ida I, Owashi T, et al. Assessment of the dexamethasone/CRH test as a state-dependent marker for hypothalamic-pituitary-adrenal (HPA) axis abnormalities in major depressive episode : a multicenter study. Neuropsychopharmacology, 2006,31 : 212-220. 被引量:1
  • 9Bao AM, Meynen G, Swaab DF. The stress system in depression and neurodegeneration: focus on the human hypothalamus. Brain Res Rev,2008,57:531-533. 被引量:1
  • 10Fehm HL, Kern W, Peters A. The selfish brain: competition for energy resources. Prog Brain Res,2006,153 : 129-140. 被引量:1

二级参考文献25

  • 1林文盛.3种抗抑郁作用的药物经济学分析[J].中国药师,2004,7(10):808-809. 被引量:7
  • 2严进,陈宜张.中枢5-羟色胺能系统与下丘脑-垂体应激激素[J].生理科学进展,1995,26(4):337-340. 被引量:8
  • 3American Psychiatry Association. Practice guidelines for the treatment of psychiatric disorders(2000): practice guideline for the treatment of patients with major depressive disorder. 2nd ed. Washington: American Psychiatric Association, 2000.429. 被引量:1
  • 4卫生部疾病控制司 中国疾病预防控制中心精神卫生中心 中华医学会精神病学分会.中国抑郁障碍防治指南[M].北京:北京大学精神卫生研究所,2003.27-54. 被引量:2
  • 5Harnov LG, Assenov V. Citalopram for the treatment of major depression in the elderly: an open naturalistic study. Eur Neuropsychopharmacol, 1997, 7 Suppl 2:S2 181. 被引量:1
  • 6Montgomery SA, Rasmussen JG. Citalopram 20 mg, citalopram 40 mg and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol, 1992, 6 Suppl 5:71-73. 被引量:1
  • 7Nyth AL, Gottfries CG, Lyby K, et al. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand,1992, 86:138-145. 被引量:1
  • 8Gill D, Hatcher S.A systematic review of the treatment of depression with antidepressant drugs in patients who also have a physical illness. J Psychosom Res, 1999, 47:131-143. 被引量:1
  • 9Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry, 2003, 27:85-102. 被引量:1
  • 10Stein DJ, Montgomery SA, Kasper S, et al. Predictors of response to pharmacotherapy with citalopram in obsessive-compulsive disorder. Int Clin Psychopharmacol, 2001, 16:357-361. 被引量:1

共引文献84

同被引文献206

引证文献13

二级引证文献92

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部